-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31

Benzinga·07/20/2026 13:36:34
Listen to the news
B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $31.